The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease

Abstract Background Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established therapy for advanced Parkinson's disease (PD). The most common genetic mutation associated with PD identified to date is the G2019S mutation of the LRRK2 gene, which is highly prevalent in the As...

Full description

Saved in:
Bibliographic Details
Published in:Parkinsonism & related disorders 2013-11, Vol.19 (11), p.1053-1056
Main Authors: Greenbaum, Lior, Israeli-Korn, Simon D, Cohen, Oren S, Elincx-Benizri, Sandra, Yahalom, Gilad, Kozlova, Evgenia, Strauss, Hanna, Molshatzki, Noa, Inzelberg, Rivka, Spiegelmann, Roberto, Israel, Zvi, Hassin-Baer, Sharon
Format: Article
Language:English
Subjects:
Aged
Cohort Studies
Deep Brain Stimulation - trends
Female
Humans
Jews - genetics
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
LRRK2
Male
Middle Aged
Mutation - genetics
Neurology
Parkinson Disease - diagnosis
Parkinson Disease - genetics
Parkinson Disease - therapy
Parkinsons disease
Protein-Serine-Threonine Kinases - genetics
STN-DBS
Subthalamic Nucleus - physiology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established therapy for advanced Parkinson's disease (PD). The most common genetic mutation associated with PD identified to date is the G2019S mutation of the LRRK2 gene, which is highly prevalent in the Ashkenazi Jewish population. The effect of STN-DBS surgery in patients carrying this mutation has not been systematically studied. We therefore performed a case-control study to evaluate the impact of the G2019S mutation status on the outcomes of bilateral STN-DBS. Methods The study sample included 39 Jewish PD patients with bilateral STN-DBS. Thirteen patients (5 females) were G2019S mutation heterozygous. The control group consisted of 26 PD patients with bilateral STN-DBS, negative for the mutation, matched (2:1) for gender, age at PD onset, and disease duration at surgery. Clinical data including the Unified PD Rating Scale scores (UPDRS), levodopa equivalent daily dose (LEDD), and clinical global impression of change (CGIC) concerning both motor and neuropsychiatric outcome- were available at 3 time points (preoperative baseline, 6–12 months and 3 years postoperatively). Results Implementing a linear mixed model, a significant improvement ( p  
ISSN:1353-8020
1873-5126
DOI:10.1016/j.parkreldis.2013.07.005